Long-term in vivo production of therapeutic proteins and development of vaccines that elicit protective levels of broadly neutralizing antibodies (bNAbs) against major pathogens face challenges. In this study, we report on an alternative gene editing …
Source link
B lymphocyte protein factories produced by hematopoietic stem cell gene editing | Science
